The addition of cetuximab to concurrent chemoradiation failed to improve survival in patients with esophageal cancer, according to results from the randomized, multicenter NRG-RTOG 0436 phase 3 trial.
https://www.healio.com/hematology-oncology/gastrointestinal-cancer/news/in-the-journals/%7Ba941dd78-c7a3-4182-a603-65763a0b313b%7D/failed-study-shows-need-for-esophageal-cancer-biomarkers
Failed study shows need for esophageal cancer biomarkers